Lenalidomide
Lenalidomide Brand names, Lenalidomide Analogs
Lenalidomide Brand Names Mixture
- No information avaliable
Lenalidomide Chemical_Formula
C13H13N3O3
Lenalidomide RX_link
No information avaliable
Lenalidomide fda sheet
Lenalidomide msds (material safety sheet)
Lenalidomide Synthesis Reference
No information avaliable
Lenalidomide Molecular Weight
259.261 g/mol
Lenalidomide Melting Point
No information avaliable
Lenalidomide H2O Solubility
Soluble in organic solvent/water mixtures, and buffered aqueous solvents. Lenalidomide is more soluble in organic solvents and low pH solutions. Solubility was significantly lower in less acidic buffers, ranging from about 0.4 to 0.5 mg/mL.
Lenalidomide State
Solid
Lenalidomide LogP
-0.318
Lenalidomide Dosage Forms
Capsules (5 and 10 mg, for oral administration)
Lenalidomide Indication
For the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
Lenalidomide Pharmacology
Lenalidomide, a thalidomide analogue, is an immunomodulatory agent possessing immunomodulatory and antiangiogenic properties. Lenalidomide inhibits the secretion of pro-inflammatory cytokines and increases the secretion of anti-inflammatory cytokines from peripheral blood mononuclear cells. Lenalidomide inhibits cell proliferation with varying effectiveness (IC50s) in some but not all cell lines. Lenalidomide is effective in inhibiting growth of Namalwa cells (a human B cell lymphoma cell line with a deletion of one chromosome 5) but is much less effective in inhibiting growth of KG-1 cells (human myeloblastic cell line, also with a deletion of one chromosome 5) and other cell lines without chromosome 5 deletions.
Lenalidomide Absorption
Rapidly absorbed following oral administration, with maximum plasma concentrations occurring between 0.625 and 1.5 hours post-dose. Co-administration with food does not alter the extent of absorption (AUC) but does reduce the maximal plasma concentration (Cmax) by 36%. The pharmacokinetic disposition of lenalidomide is linear.
Lenalidomide side effects and Toxicity
The most frequently reported adverse events were related to blood and lymphatic system disorders, skin and subcutaneous tissue disorders, gastrointestinal disorders, and general disorders and administrative site conditions.
Lenalidomide Patient Information
Lenalidomide Organisms Affected
Humans and other mammals
